Wall Street Zen Upgrades Nyxoah (NASDAQ:NYXH) to “Hold”

Nyxoah (NASDAQ:NYXH) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other analysts have also recently issued reports on the stock. Piper Sandler restated an “overweight” rating and set a $7.00 target price (down from $9.00) on shares of Nyxoah in a research note on Wednesday, May 13th. Robert W. Baird set a $2.85 price objective on Nyxoah in a report on Thursday, July 9th. Stifel Nicolaus decreased their target price on Nyxoah from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Wednesday, June 17th. Finally, Weiss Ratings cut Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.96.

Nyxoah Price Performance

NYXH opened at $1.40 on Friday. Nyxoah has a 1-year low of $1.26 and a 1-year high of $8.59. The stock’s fifty day simple moving average is $1.80 and its 200 day simple moving average is $3.06. The company has a current ratio of 0.99, a quick ratio of 0.88 and a debt-to-equity ratio of 0.53. The stock has a market cap of $54.26 million, a PE ratio of -0.56 and a beta of 1.62.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.11. Nyxoah had a negative net margin of 543.21% and a negative return on equity of 163.73%. The firm had revenue of $7.38 million during the quarter, compared to analysts’ expectations of $7.05 million. As a group, research analysts expect that Nyxoah will post -1.67 earnings per share for the current year.

Institutional Investors Weigh In On Nyxoah

A number of large investors have recently modified their holdings of NYXH. Heights Capital Management Inc. bought a new position in shares of Nyxoah in the 4th quarter valued at $3,575,000. Deutsche Bank AG lifted its position in shares of Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after buying an additional 10,000 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Nyxoah during the 3rd quarter worth $98,000. Bank of America Corp DE boosted its stake in Nyxoah by 152.7% in the third quarter. Bank of America Corp DE now owns 19,878 shares of the company’s stock valued at $91,000 after buying an additional 12,012 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its stake in Nyxoah by 35.6% in the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after buying an additional 3,353 shares in the last quarter.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep?disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.